{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:42:52Z","timestamp":1787024572684,"version":"build-2736575974"},"reference-count":46,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["PPA"],"DOI":"10.2147\/ppa.s485838","type":"journal-article","created":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T04:00:14Z","timestamp":1729915214000},"page":"2159-2167","source":"Crossref","is-referenced-by-count":6,"title":["Novel Bispecific T-Cell Engagers for the Treatment of Relapsed B Cell Non-Hodgkin Lymphomas: Current Knowledge and Treatment Considerations"],"prefix":"10.2147","volume":"Volume 18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0308-7303","authenticated-orcid":true,"given":"Ben","family":"Varon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7076-6501","authenticated-orcid":true,"given":"Netanel","family":"Horowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hazim","family":"Khatib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,10]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"ref2","unstructured":"Cancer Stat Facts: NHL \u2014 diffuse Large B-Cell Lymphoma (DLBCL)."},{"key":"ref3","unstructured":"Cancer Stat Facts: NHL \u2014 follicular Lymphoma."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1002\/ajh.24086","volume":"90","author":"Al-Hamadani","year":"2015","journal-title":"Am J Hematol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.3324\/haematol.2016.148809","volume":"101","author":"Perry","year":"2016","journal-title":"Haematologica"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1046\/j.1365-2141.2003.04749.x","volume":"124","author":"M\u00f8ller","year":"2004","journal-title":"Br J Haematol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.pathol.2017.09.006","volume":"50","author":"Li","year":"2018","journal-title":"Pathology"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/10428194.2010.504872","volume":"51","author":"Hui","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1007\/s00277-012-1491-5","volume":"91","author":"Prakash","year":"2012","journal-title":"Ann Hematol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.beha.2004.06.002","volume":"18","author":"Rohatiner","year":"2005","journal-title":"Best Pract Res Clin Haematol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/bjh.16872","volume":"191","author":"McNamara","year":"2020","journal-title":"Br J Haematol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1200\/JCO.2006.09.3260","volume":"25","author":"Montoto","year":"2007","journal-title":"J Clin Oncol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"J Clin Oncol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/14651858.CD013365.pub2","volume":"2021","author":"Ernst","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1002\/ajh.26737","volume":"97","author":"Jacobsen","year":"2022","journal-title":"Am J Hematol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"5835","DOI":"10.1182\/bloodadvances.2022008150","volume":"6","author":"Salles","year":"2022","journal-title":"Blood Adv"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/icb.2014.93","volume":"93","author":"Huehls","year":"2015","journal-title":"Immunol Cell Biol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01084-4","volume":"14","author":"Tian","year":"2021","journal-title":"J Hematol Oncol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1007\/s40262-016-0405-4","volume":"55","author":"Zhu","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"3098","DOI":"10.1080\/10428194.2021.1953016","volume":"62","author":"Minson","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"4785","DOI":"10.1158\/1078-0432.CCR-18-0455","volume":"24","author":"Bacac","year":"2018","journal-title":"Clin Cancer Res"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/nejmoa2206913","volume":"387","author":"Dickinson","year":"2022","journal-title":"N Engl J Med"},{"key":"ref23","unstructured":"FDA announcement of accelerated approval to glofitamab-gxbm for selected relapsed or refractory large B-cell lymphomas, Accessed June 21, 2024. Available from: https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-grants-accelerated-approval-glofitamab-gxbm-selected-relapsed-or-refractory-large-b-cell."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ebiom.2019.102625","volume":"52","author":"Engelberts","year":"2020","journal-title":"EBioMedicine"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1016\/S0140-6736(21)00889-8","volume":"398","author":"Hutchings","year":"2021","journal-title":"Lancet"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1200\/JCO.22.01725","volume":"41","author":"Thieblemont","year":"2022","journal-title":"J Clin Oncol"},{"key":"ref27","unstructured":"FDA announcement of accelerated approval to epcoritamab-bysp for relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma, Accessed June 21, 2024. Available from: https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-grants-accelerated-approval-epcoritamab-bysp-relapsed-or-refractory-diffuse-large-b-cell."},{"key":"ref28","first-page":"1165","volume":"50","author":"Lori","year":"2023","journal-title":"Cancer Res Preventi Treatm"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Avivi I, Kim WS, Ko PS, et al. Subcutaneous Epcoritamab Plus Lenalidomide in Patients with Relapsed\/Refractory Diffuse Large B-Cell Lymphoma from EPCORE NHL-5. Oral abstract 438 in ASH Annual Meeting and Exposition. Available from: https:\/\/ash.confex.com\/ash\/2023\/webprogram\/Paper180089.htmlx.com\/ash\/2023\/webprogram\/Paper180089.html\/. Accessed October 19, 2024.","DOI":"10.1182\/blood-2023-180089"},{"key":"ref30","unstructured":"FDA announcement of accelerated approval to epcoritamab-bysp for relapsed or refractory follicular lymphoma, Accessed September 30, 2024. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-epcoritamab-bysp-relapsed-or-refractory-follicular-lymphom."},{"key":"ref31","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1200\/JCO.21.00931","volume":"40","author":"Budde","year":"2021","journal-title":"J Clin Oncol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","volume":"23","author":"Budde","year":"2022","journal-title":"Lancet Oncol"},{"key":"ref33","unstructured":"FDA announcement of accelerated approval of mosunetuzumab for relapsed or refractory follicular lymphoma. Accessed June 22, 2024. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-mosunetuzumab-axgb-relapsed-or-refractory-follicular-lymphoma."},{"key":"ref34","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1080\/10428194.2023.2262066","volume":"64","author":"McGough","year":"2023","journal-title":"Leuk Lymphoma"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"4926","DOI":"10.1182\/bloodadvances.2022009260","volume":"7","author":"Bartlett","year":"2023","journal-title":"Blood Adv"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/s41591-023-02726-5","volume":"30","author":"Budde","year":"2024","journal-title":"Nat Med"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"e327","DOI":"10.1016\/S2352-3026(22)00072-2","volume":"9","author":"Bannerji","year":"2022","journal-title":"Lancet Haematol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1182\/blood-2023-179818","volume":"142","author":"Ayyappan","year":"2023","journal-title":"Blood"},{"key":"ref39","unstructured":"Regeneron. Regeneron official update on FDA status of odronextamab. Accessed June 22, 2024. Available from: https:\/\/investor.regeneron.com\/news-releases\/news-release-details\/regeneron-provides-update-biologics-license-application\/."},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.3324\/haematol.2017.173583","volume":"102","author":"Lugtenburg","year":"2017","journal-title":"Haematologica"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"459","DOI":"10.3111\/13696998.2014.914033","volume":"17","author":"Rule","year":"2014","journal-title":"J Med Econ"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"e370","DOI":"10.1016\/S2352-3026(20)30070-3","volume":"7","author":"Mateos","year":"2020","journal-title":"Lancet Haematol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"21480","DOI":"10.1002\/cam4.6699","volume":"12","author":"Pradelli","year":"2023","journal-title":"Cancer Med"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"e542","DOI":"10.1200\/OP.22","volume":"19","author":"Soefje","year":"2024","journal-title":"JCO Oncology Practice"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1177\/0272989X15598529","volume":"35","author":"Kashaf","year":"2015","journal-title":"Med Decis Mak"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"34693","DOI":"10.7759\/cureus.34693","volume":"15","author":"Ahmed","year":"2023","journal-title":"Cureus"}],"container-title":["Patient Preference and Adherence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/article\/download\/96729","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/article\/download\/96729","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T04:00:20Z","timestamp":1729915220000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/novel-bispecific-t-cell-engagers-for-the-treatment-of-relapsed-b-cell--peer-reviewed-fulltext-article-PPA"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":46,"URL":"https:\/\/doi.org\/10.2147\/ppa.s485838","relation":{},"ISSN":["1177-889X"],"issn-type":[{"value":"1177-889X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10]]}}}